Johnson & Johnson announces first head-to-head study comparing IMAAVY with an alternative FcRn blocker in generalized myasthenia gravis at AANEM Annual Meeting
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
TREMFYA® , the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease activity and severity through substantial reduction in Sjögren's-related autoantibodies
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
SAGA Metals Mobilizes Final Team for Major Drill Program at Radar Project in Labrador, Targeting Maiden Mineral Resource Estimate & Provides Corporate Update
